BioSig Technologies Inc said it has entered into a feasibility study with Haifa, Israel-based Technion Research & Development Foundation Ltd.
The Westport, Connecticut-based company said that the feasibility program will be led by Joachim Behar, Head of the Artificial Intelligence in Medicine Laboratory (AIMLab) at Technion.
Under the terms of the program, the ECG signals supplied by the PURE EP System, the company’s signal processing technology for arrhythmia care, will be analyzed in the context of developing AI-powered algorithms for atrial fibrillation ablation procedures.
“Artificial Intelligence is promptly becoming an essential tool for increasing efficiency and driving value in many sectors of healthcare, but predictive insights that form the foundation for machine learning solutions are dependant on the high-quality input data,” said Kenneth L. Londoner, CEO of BioSig in a statement.
READ: BioSig Technologies adds to its growing clinical footprint in Texas
He added: “Our clinical work provides us with vast volumes of smaller, often undetectable cardiac signals that hold additional diagnostic information, and we are thrilled to partner with Prof. Behar and his Technion team to take our AI work to the next level.”
Londoner noted that the Technion team’s expertise in developing deep learning systems for ECG records is “invaluable to this program, and we look forward to reporting on the progress of this promising new project.”
Technion, the Israel Institute of Technology, is a public research university. Over the years, Technion has established itself as a leading academic institution in Artificial Intelligence (AI). It is currently ranked as number one in AI in Europe and 15th in the world, with 100 faculty members engaged in areas across the AI spectrum.
“The laboratory for artificial intelligence in medicine (AIMLab) at the Technion focuses on the usage of advanced signal processing and machine learning in medicine within the context of physiological time series analysis with a specific focus in cardiology where we have 10 years of expertise in processing and analyzing the ECG signal,” said Technion's Joachim Behar.
He noted: “In particular, in our most recent research we have developed robust deep learning algorithms for AF diagnosis and risk prediction working on large databases, totaling over a million ECG recordings. Our new partnership with BioSig is aligned with this desire to contribute and impact the medical field through AI-powered algorithms to support clinical decision-making in cardiology."
One in 18 Americans suffers from a cardiac arrhythmia. Atrial fibrillation is the most common arrhythmia type, affecting over 33 million people worldwide, including over 6 million in the US.
The number of people suffering from atrial fibrillation is expected to reach 8-12 million by 2050. According to the Centers for Disease Control and Prevention (CDC), atrial fibrillation causes more than 750,000 hospitalizations in the US each year, resulting in approximately $6 billion in healthcare spending annually.
BioSig’s PURE EP is a US Food and Drugs Administration (FDA) 510(k) cleared non-invasive class II device that aims to drive procedural efficiency and efficacy in cardiac electrophysiology.
To date, over 70 physicians have completed over 1600 patient cases with the PURE EP System. Clinical data acquired by the PURE EP System in a multi-center study at Texas Cardiac Arrhythmia Institute at St. David’s Medical Center, Mayo Clinic Jacksonville, and Massachusetts General Hospital was recently published in the Journal of Cardiovascular Electrophysiology and is available electronically with open access via the Wiley Online Library.
The study results showed 93% consensus across the blinded reviewers with a 75% overall improvement in intracardiac signal quality and confidence in interpreting PURE EP signals over conventional sources.
Contact Ritika at ritika@proactiveinvestors.com